Two ventures awarded Stage II by INCATE
December 16, 2024 – INCATE (INCubator for Antibacterial Therapies in [...]
2024: the year in review
Just before turning the page to 2025, it's a moment [...]
Invitris closes major deal in the European Market
We are thrilled to announce a significant milestone for Invitris—a [...]
Celebrating milestones: a remarkable year for Xiretsa
2024 has been a transformative year for Xiretsa, filled with [...]
Call for Submissions: Advances in Bacteriophage Research and Development with Therapeutic Applications
INCATE is pleased to invite researchers, clinicians, and industry experts [...]
Kinzbio: forging ahead in Phage-Based precision antimicrobials
Kinzbio’s mission is to harness the power of phages—nature's precision [...]
BamA Inhibitor Project Secures €180k DATIpilot Grant
The BamA Inhibitor project (Justus-Liebig-University Giessen) has been awarded a [...]
Shionogi and INCATE renew partnership to continue supporting innovators fighting antimicrobial resistance
November 5th, 2024 – INCATE (the INCubator for Antibacterial Therapies [...]
Great news for the hemolysin inhibitor program!
© Marek Kruszewski Researchers from the Helmholtz Centre [...]
“Surviving Superbugs – A Dance To Resist”
credits: Interfinity On April 9th, 2025, 20:30, at [...]
